BioAge Labs (NASDAQ:BIOA) Upgraded to “Hold” at UBS Group

BioAge Labs (NASDAQ:BIOA) was upgraded by analysts at UBS Group to a “hold” rating in a research note issued to investors on Sunday, Zacks reports.

Several other equities research analysts have also commented on the stock. Needham & Company LLC reduced their price target on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a report on Friday, July 31st. Wall Street Zen downgraded shares of BioAge Labs from a “sell” rating to a “strong sell” rating in a research report on Saturday. Jefferies Financial Group set a $21.00 price target on BioAge Labs in a research note on Friday, July 31st. Weiss Ratings cut shares of BioAge Labs from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, October 8th. Finally, Roth Capital reissued a “buy” rating and issued a $25.00 price target on shares of BioAge Labs in a report on Wednesday, September 9th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $33.00.

BioAge Labs Stock Performance

Shares of NASDAQ BIOA opened at $5.57 on Friday. The stock’s 50 day moving average price is $8.75 and its 200-day moving average price is $15.39. BioAge Labs has a twelve month low of $5.04 and a twelve month high of $25.95.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.58) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.07. The firm had revenue of $2.45 million for the quarter. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%. As a group, research analysts anticipate that BioAge Labs will post -2.45 EPS for the current fiscal year.

Institutional Trading of BioAge Labs

Several large investors have recently modified their holdings of BIOA. Engineers Gate Manager LP acquired a new stake in shares of BioAge Labs during the 2nd quarter valued at approximately $344,000. Squarepoint Ops LLC boosted its stake in BioAge Labs by 23.3% in the second quarter. Squarepoint Ops LLC now owns 68,436 shares of the company’s stock valued at $1,677,000 after acquiring an additional 12,916 shares during the period. Corient Private Wealth LP raised its position in shares of BioAge Labs by 76.7% during the 2nd quarter. Corient Private Wealth LP now owns 40,258 shares of the company’s stock worth $987,000 after purchasing an additional 17,476 shares during the period. Yiheng Capital Management L.P. bought a new position in BioAge Labs during the 2nd quarter worth $4,180,000. Finally, Wellington Management Group LLP boosted its holdings in shares of BioAge Labs by 39.9% during the second quarter. Wellington Management Group LLP now owns 94,656 shares of the company’s stock valued at $2,320,000 after acquiring an additional 26,975 shares during the period.

BioAge Labs Company Profile

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines for diseases associated with aging. The company uses human longevity data, machine learning and biology research to identify therapeutic targets and develop treatments intended to address the biological drivers of aging and age-related decline.

BioAge’s pipeline has included azelaprag, formerly known as BGE-105, an investigational small-molecule agonist of the apelin receptor. The company has evaluated azelaprag in clinical studies involving muscle function and has also investigated its potential use in combination with incretin-based medicines for obesity.